Presentations

      Toxicological Characterization of the Mentholated Heat-not-Burn Product THS2.2M in a 90-Day OECD Inhalation Study

      Oviedo, A.; Lebrun, S.; Rodrigo, G.; Ho, J.; Vuillaume, G.; Vanscheeuwijck, P.; Hayes, A. W.; Hoeng, J.; Peitsch, M.

      Conference date
      Mar 17, 2016
      Conference name
      Society of Toxicology (SOT) 2016
      Link to more information
      Topic
      Summary

      The toxicity of aerosol from the mentholated Tobacco Heating System (THS2.2M), a candidate modified risk tobacco product (cMRTP), was characterized in Sprague-Dawley rats in a subchronic inhalation study following the OECD Test Guideline 413, and compared to the one inherent to cigarette smoke (CS) from mentholated reference cigarettes (MRC). Rats were nose-only exposed for 6 hours per day, 5 days per week for 90 days to either filtered air, CS from MRC to a target nicotine concentration of 23 μg/L (with 2 menthol concentrations in CS) or to aerosol from THS2.2M to 3 different target nicotine concentrations (15, 23 and 50 μg/L). The analysis of the test atmosphere showed a reduction of up to 90% and 98% in aldehydes and CO, respectively when compared to CS from MRC. Aerosols were reproducibly taken up by the rats as indicated by determination of carboxyhemoglobin and selected aerosol constituents and their metabolites in blood. Exposure to CS resulted in typical smoke related toxicological effects consistent with findings reported in previous studies. Histopathological findings in the respiratory tract and pulmonary inflammation in THS2.2M exposed groups were significantly lower in severity or absent when compared to MRCexposed groups. This was consistent with reduced inflammatory cells infiltration and cytokine expression in bronchioalveolar lung fluid suggesting reduced inflammatory processes as compared to the response to CS exposure. Overall, the data demonstrate that aerosol generated by THS2.2M causes much lower systemic and respiratory tract toxicity than CS from mentholated combustible cigarettes. Furthermore, no menthol related effects were detected after THS2.2M aerosol or MRC CS-exposure. 

      Related Publications

      A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

      Pre-clinical Toxicology

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

      Pre-clinical Toxicology

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.